Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets 'Undruggable' cancer mutation in major trial

NCT ID NCT05410145

Recruiting now Disease control Sponsor: D3 Bio (Wuxi) Co., Ltd Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a new oral medication called D3S-001 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe dose, see how the body processes the drug, and get early signs of whether it helps control the cancer. About 442 participants with various advanced cancers will take the pill daily in 21-day cycles.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • D3 Bio Investigative Site 0101

    RECRUITING

    Malvern, Victoria, 3144, Australia

  • D3 Bio Investigative Site 0102

    RECRUITING

    Sydney, New South Wales, 2109, Australia

  • D3 Bio Investigative Site 0103

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • D3 Bio Investigative Site 0104

    RECRUITING

    Bedford Park, 5042, Australia

  • D3 Bio Investigative Site 0105

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • D3 Bio Investigative Site 0201

    WITHDRAWN

    Seoul, 138-736, South Korea

  • D3 Bio Investigative Site 0202

    RECRUITING

    Seoul, 06591, South Korea

  • D3 Bio Investigative Site 0203

    RECRUITING

    Seoul, 120-752, South Korea

  • D3 Bio Investigative Site 0204

    RECRUITING

    Cheongju-si, North Chungcheong, 28644, South Korea

  • D3 Bio Investigative Site 0301

    RECRUITING

    Shanghai, Shanghai Municipality, 200030, China

  • D3 Bio Investigative Site 0302

    RECRUITING

    Shenyang, Liaoning, 110042, China

  • D3 Bio Investigative Site 0303

    RECRUITING

    Beijing, Beijing Municipality, 100036, China

  • D3 Bio Investigative Site 0304

    RECRUITING

    Nanchang, Jiangxi, 330008, China

  • D3 Bio Investigative Site 0305

    RECRUITING

    Hangzhou, Hangzhou, 310022, China

  • D3 Bio Investigative Site 0306

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • D3 Bio Investigative Site 0307

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • D3 Bio Investigative Site 0308

    RECRUITING

    Shanghai, Shanghai Municipality, 201801, China

  • D3 Bio Investigative Site 0309

    RECRUITING

    Wuhan, Hubei, 43000, China

  • D3 Bio Investigative Site 0310

    RECRUITING

    Jinan, Shandong, 250117, China

  • D3 Bio Investigative Site 0311

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • D3 Bio Investigative Site 0312

    RECRUITING

    Wuhan, Hubei, 430079, China

  • D3 Bio Investigative Site 0313

    RECRUITING

    Zhengzhou, 450003, China

  • D3 Bio Investigative Site 0314

    RECRUITING

    Hefei, 230000, China

  • D3 Bio Investigative Site 0315

    RECRUITING

    Changsha, 410013, China

  • D3 Bio Investigative Site 0316

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • D3 Bio Investigative Site 0401

    RECRUITING

    Detroit, Michigan, 48202-2608, United States

  • D3 Bio Investigative Site 0402

    RECRUITING

    Orange, California, 92868, United States

  • D3 Bio Investigative Site 0403

    RECRUITING

    Houston, Texas, 77030, United States

  • D3 Bio Investigative Site 0404

    RECRUITING

    Denver, Colorado, 80218-1238, United States

  • D3 Bio Investigative Site 0405

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • D3 Bio Investigative Site 0406

    RECRUITING

    Sarasota, Florida, 34232-6410, United States

  • D3 Bio Investigative Site 0407

    RECRUITING

    Palo Alto, California, 94304-2205, United States

  • D3 Bio Investigative Site 0501

    RECRUITING

    Shatin, 999077, Hong Kong

  • D3 Bio Investigative Site 0601

    RECRUITING

    Kashiwa, 277-8577, Japan

  • D3 Bio Investigative Site 0602

    RECRUITING

    Tokyo, 104-0045, Japan

  • D3 Bio Investigative Site 0701

    RECRUITING

    Barcelona, 08035, Spain

  • D3 Bio Investigative Site 0702

    RECRUITING

    Valencia, 46026, Spain

  • D3 Bio Investigative Site 0703

    RECRUITING

    Valencia, 46010, Spain

  • D3 Bio Investigative Site 0704

    RECRUITING

    Madrid, 28046, Spain

  • D3 Bio Investigative Site 0705

    RECRUITING

    Madrid, 28050, Spain

  • D3 Bio Investigative Site 0706

    RECRUITING

    Barcelona, 08023, Spain

  • D3 Bio Investigative Site 0801

    RECRUITING

    Rennes, 35033, France

  • D3 Bio Investigative Site 0802

    RECRUITING

    Villejuif, 94805, France

  • D3 Bio Investigative Site 0803

    RECRUITING

    Lyon, 69373, France

  • D3 Bio Investigative Site 0804

    RECRUITING

    Bordeaux, 33000, France

  • D3 Bio Investigative Site 0901

    RECRUITING

    Rome, 00144, Italy

  • D3 Bio Investigative Site 0902

    RECRUITING

    Milan, 20141, Italy

  • D3 Bio Investigative Site 0903

    RECRUITING

    Siena, 53100, Italy

  • D3 Bio Investigative Site 0904

    RECRUITING

    Naples, 80131, Italy

  • D3 Bio Investigative Site 0905

    RECRUITING

    Candiolo, 10060, Italy

  • D3 Bio Investigative Site 1002

    RECRUITING

    Hamburg, 20249, Germany

  • D3 Bio Investigative Site 1003

    RECRUITING

    Cologne, North Rhine-Westphalia, 45147, Germany

Conditions

Explore the condition pages connected to this study.

KRAS P.G12C